News for Passage Bio, Inc. (PASG)

Transaction Overview On April 24, 2025, Orbimed Advisors LLC executed a strategic transaction involving Passage Bio Inc (NASDAQ: PASG). The firm reduced its hol

Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, a

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. ( PASG), a clinical stage genetic medicines company focused on improving the lives of patien

On January 14, 2025, Orbimed Advisors LLC executed a significant transaction involving Passage Bio Inc (PASG). The firm reduced its holdings in the genetic medi

**media[511576]**

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

On January 8, 2025, Orbimed Advisors LLC made a strategic decision to reduce its holdings in Passage Bio Inc (NASDAQ: PASG). The firm decreased its position by

On December 27, 2024, Lynx1 Capital Management LP (Trades, Portfolio) made a significant move by acquiring an additional 373,645 shares of Passage Bio Inc (PASG

On December 20, 2024, Orbimed Advisors LLC executed a strategic transaction involving Passage Bio Inc (PASG), a genetic medicines company. The firm reduced its

On December 11, 2024, Orbimed Advisors LLC executed a strategic transaction involving Passage Bio Inc (PASG). The firm reduced its holdings in the biotechnology

On December 6, 2024, ORBIMED ADVISORS LLC (Trades, Portfolio) made a significant move by reducing its holdings in Passage Bio Inc (NASDAQ: PASG). The firm decre

Insider Activity Roundup: Wednesday's Top Buys and Sells Revealed

On November 27, 2024, Lynx1 Capital Management LP (Trades, Portfolio) made a significant move by acquiring an additional 456,353 shares of Passage Bio Inc (NASD

Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why the best days are ahead for VYGR stock.

The overall frontotemporal dementia market is expected to rise due to increasing prevalence cases over the globe and thus the surge in treatment options....

On Wednesday, 311 stocks hit new 52-week lows.

Read Investment Analysts’ Downgrades for June 8th (APTV, ATTRF, BNS, BROS, CGC, CNQ, CZOO, DEO, FLNG, GTLS) at ETF Daily News

Read Stock Analysts’ Upgrades for May 28th (AMSC, ARW, BKE, CACI, COTY, HLF, JBSS, LOCL, LXRX, MGEE) at ETF Daily News